PMC 1204285
Hydrophobic residues in p53 TAD2 are critical for interaction with FOXO4 FHD Based on the significance of both the TAD2 region and the C-terminus of p53 in interacting with the FOXO4 FHD, we attempted to develop an inhibitor targeting the FOXO4-p53 interaction
The therapeutic value of bifidobacteria in cardiovascular disease
Any extra-pharmaceutical human use falls outside the legitimate product scope, and lot-to-lot traceability via certified COA constitutes the first regulatory defense line for purchasing laboratories
Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone bitartrate and acetaminophen tablets and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression (see WARNINGS), particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved
References Wang, Y
